supp.fit

Niacin: study protocols

217 study groups say how much Niacin participants took a day. These are the doses the studies gave. They are not a recommendation.

Niacin: what the research found →

Dose per serving from products

16,769 products in our catalogue print how much Niacin a serving holds.

Most common: 10 mg to 25 mg, 42% of 16,769 products.

Dose per servingProducts
1 mg or less
614
1 mg to 2.5 mg
542
2.5 mg to 5 mg
1,439
5 mg to 10 mg
2,128
10 mg to 25 mg
7,068
25 mg to 50 mg
3,044
50 mg to 100 mg
1,132
over 100 mg
802

Dose per serving from research

211 study groups in 142 studies say how much Niacin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 43% of 211 study groups.

Daily doseStudy groups
25 mg or less
7
25 mg to 50 mg
13
50 mg to 100 mg
7
100 mg to 250 mg
2
250 mg to 500 mg
16
500 mg to 1 g
48
1 g to 2.5 g
91
2.5 g to 5 g
25
over 5 g
2

Commonly used together

35 of 217 study groups took Niacin with something else. Shown: what 3 or more different studies gave. The 10 most common of 11.

What was given together, not what works together.

Taken withStudy groups
Riboflavin
13
Vitamin C
11
Vitamin B12
9
Coenzyme Q10
8
Folic Acid
7
Caffeine
6
Beta-Alanine
5
Thiamine
5
Vitamin E
5
Vitamin B6
4

217 study groups

Study
Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial
2024 · nicotinamide · Adults with stage IV lung adenocarcinoma and EGFR mutations
1 g—55
Efficacy of intermittent topical 5-fluorouracil 5% and oral nicotinamide in the skin field cancerization: a randomized clinical trial
2021 · Nicotinamide · Adults with actinic keratoses (AKs), mean age 71.6 years; 36 patients were randomized across study groups
1 g120 days18
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
2015 · nicotinamide group · Adults with at least two nonmelanoma skin cancers in the previous 5 years
1 g1 year—
Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
2007 · Niacin · Men and women older than 30 years with known coronary vascular disease, receiving statin therapy and with LDL cholesterol below 130 mg/dL and HDL cholesterol below 45 mg/dL
500 mg1 year87
Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions
1997 · aspirin 325 mg pretreatment · Healthy adults aged 35–65 years, male and female
500 mg4 days42
Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions
1997 · aspirin 650 mg pretreatment · Healthy adults aged 35–65 years, male and female
500 mg4 days42
The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
2003 · niacin group · Healthy volunteers aged 20–60 years
500 mg1 day33
Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study
2017 · Group 1 (cases) · Organ transplant recipients with single or multiple actinic keratoses; age and sex not reported
500 mg26 weeks19
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia
2009 · NER starting dose 500 mg/day · Patients with dyslipidemia; age and sex not specified
500 mg4 weeks—
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
2013 · ERN/LRPT · Adults with pre-existing occlusive arterial disease at high risk of vascular events, receiving statin-based LDL-lowering therapy; mean age 64.9 years, 82.7% male
2 g1424 days12,838
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
2019 · niacin-laropiprant · Patients at high risk of vascular disease
2 g1424 days12,838
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial
2012 · E/S+N · Men and women aged 18–79 with type IIa/IIb hyperlipidemia; some had diabetes at baseline and some did not.
2 g64 weeks670
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
1990 · niacin and colestipol · Men aged 62 or younger with apolipoprotein B levels of at least 125 mg/dL, documented coronary artery disease, and a family history of vascular disease
4 g913 days48
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)
2013 · Simvastatin & Niacin · Men younger than 63 and women younger than 70 with clinical coronary disease, low HDL cholesterol, and restricted LDL cholesterol and triglycerides
2 g3 years33
Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group
1994 · NCT · Patients with recent-onset insulin-dependent diabetes, diagnosed less than 4 weeks earlier; age and sex not reported
25 mg/kg1 year30
Nicotinamide and tetracycline therapy of bullous pemphigoid
1994 · nicotinamide and tetracycline group · Patients with bullous pemphigoid; age and sex not reported
1.5 g1 year12
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial
2016 · extended-release niacin (ERN) · Adults with established stable atherosclerotic cardiovascular disease, low HDL-C, elevated triglycerides, and LDL-C below 180 mg/dL
2 g3 years—
Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)
1995 · niacin plus colestipol · Men aged 62 years or younger with coronary artery disease and apolipoprotein B levels of at least 125 mg/dL
4 g913 days—
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B
1993 · colestipol plus niacin intensive therapy · Asymptomatic men with apolipoprotein B ≥125 mg/dL, a positive family history, and coronary atherosclerosis
4 g913 days—
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
2008 · ERN · Adults with dyslipidaemia (primary hypercholesterolaemia or mixed dyslipidaemia)
1 g24 weeks543
Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
2025 · COVit-2 nicotinamide · Adults aged 18–75 with recent mild-to-moderate COVID-19 and at least one symptom; the RFITT primary-analysis population also had at least one risk factor for severe COVID-19
1 g4 weeks448
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial
2008 · ER niacin 1 g → placebo (N1/P/P) · Men and women aged 18–70 for whom extended-release niacin treatment was appropriate
1 g7 days51
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial
2008 · ER niacin 1 g (N1/N1/N1) · Men and women aged 18–70 for whom extended-release niacin treatment was appropriate
1 g8 weeks45
Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans
2012 · Oral nicotinamide · Healthy volunteers; age and sex not reported
1 g7 days30
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 18.75 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 37.5 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 75 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 150 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—
Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study
2009 · niacin (N) · Patients with coronary artery disease; age and sex not specified
1 g12 weeks—
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia
2009 · NER starting dose 1000 mg/day · Patients with dyslipidemia; age and sex not specified
1 g4 weeks—
Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study
2013 · nicotinamide group · Adults with chronic kidney disease and refractory uremic pruritus; age and sex not reported
1 g4 weeks—
Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial
2014 · ERN monotherapy · Men and women aged 20–60 years with plasma HDL-C below 40 mg/dL
1 g7 days—
Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial
2014 · ERN/laropiprant · Men and women aged 20–60 years with plasma HDL-C below 40 mg/dL
1 g7 days—
Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group
1994 · NCT + CyA · Patients with recent-onset insulin-dependent diabetes, diagnosed less than 4 weeks earlier; age and sex not reported
25 mg/kg1 year30
Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy
2013 · ER niacin · Adults with established coronary artery disease receiving high-dose statin therapy; mean age 57.9 years
1.5 g90 days66
Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial
2020 · nicotinamide, first dose period · adults with diagnosed and treated glaucoma; age and sex not specified
1.5 g6 weeks57
Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial
2020 · nicotinamide, second dose period · adults with diagnosed and treated glaucoma; age and sex not specified
3 g6 weeks57
Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study
1994 · Group A · Patients aged 5–35 years with recent-onset insulin-dependent diabetes mellitus
25 mg/kg1 year18
Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study
1994 · Group B · Patients aged 5–35 years with recent-onset insulin-dependent diabetes mellitus
25 mg/kg1 year18
High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution
2002 · niacin-treated patients · HIV-infected patients with intra-abdominal fat area greater than 70 cm²
3 g1 year16
Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment
2006 · niacin group · men with isolated low HDL cholesterol and reduced flow-mediated dilation; age not reported
1.5 g90 days11
Effect of altering substrate availability on metabolism and performance during intense exercise
2000 · NA (carbohydrate + nicotinic acid) · Seven highly trained men
20 mg/kg1 day7
Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation
2006 · reformulated niacin ER · healthy male volunteers
2 g1 day—
Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation
2006 · commercial niacin ER · healthy male volunteers
2 g1 day—
Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation
2007 · Placebo with niacin ER · Healthy men
2 g1 day—
Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients
2010 · niacin · Adults with statin-treated type 2 diabetes and endothelial dysfunction; LDL-cholesterol ≤2.5 mmol/L
1.5 g20 weeks—
Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia
2011 · niacin group · Men with erectile dysfunction and dyslipidemia
1.5 g12 weeks—
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
2010 · NER/S (niacin extended-release/simvastatin) · Men and women aged 21 years or older with primary type II hyperlipidemia or mixed dyslipidemia
1 g12 weeks82
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])
2003 · niacin ER/lovastatin · Adults with elevated LDL cholesterol and low HDL cholesterol, with or without coronary artery disease
1 g16 weeks—
Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia
1991 · 1000 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles
1 g——
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus
2012 · ERN/LRPT · Patients with type 2 diabetes mellitus; age and sex not specified
1 g12 weeks—
Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
1994 · nicotinic acid · Patients with type IIa or IIb primary hypercholesterolemia; age and sex not reported
1 g88 weeks—
Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
1994 · combination therapy · Patients with type IIa or IIb primary hypercholesterolemia; age and sex not reported
1 g88 weeks—
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)
2013 · Simvastatin, Niacin & Antioxidant vitamins · Men younger than 63 and women younger than 70 with clinical coronary disease, low HDL cholesterol, and restricted LDL cholesterol and triglycerides
2 g3 years39
Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren
2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified
16 mg335 days—
Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal
2003 · Multiple micronutrients · Pregnant women in rural Nepal
20 mg——
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial
2008 · ER niacin 1 g → ER niacin 2 g (N1/N1/N2) · Men and women aged 18–70 for whom extended-release niacin treatment was appropriate
3 g8 weeks46
Apple pectin for the reduction of niacin-induced flushing
2013 · apple pectin · Niacin-naïve subjects; age and sex not specified
1 g1 day25
Apple pectin for the reduction of niacin-induced flushing
2013 · apple pectin + aspirin · Niacin-naïve subjects; age and sex not specified
1 g1 day25
Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation
2007 · Aspirin 30 minutes before niacin ER · Healthy men
2 g1 day—
Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation
2007 · Aspirin concomitantly with niacin ER · Healthy men
2 g1 day—
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group
1998 · immediate-release niacin · Patients with combined hyperlipidemia or isolated hypertriglyceridemia
3 g12 weeks53
Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease
1997 · Regular niacin regimen · 29 male patients with hyperlipidemia and coronary artery disease
2 g240 days29
Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial
2011 · treatment group · Korean adults with mixed dyslipidemia
1.5 g8 weeks25
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins
2008 · extended-release niacin (Niaspan) · men aged 44–69 with combined hyperlipidemia
2 g12 weeks5
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins
2008 · extended-release niacin plus lovastatin (Advicor) · men aged 44–69 with combined hyperlipidemia
2 g12 weeks5
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia
2008 · E/S + N · Patients with type IIa or IIb hyperlipidemia
2 g24 weeks—
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia
2008 · N · Patients with type IIa or IIb hyperlipidemia
2 g24 weeks—
Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy
2009 · simvastatin 20 mg/Niacin-ER 2G (S20/N) · Adults aged 18–90 with carotid atherosclerosis
2 g1 year—
Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia
1991 · 2000 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles
2 g——
Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia
1991 · 1500 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles
1.5 g——
Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia
1991 · 1250 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles
1.25 g——
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome
2010 · E/S (10/20 mg) + extended-release niacin for 64 weeks · Hyperlipidaemic patients with diabetes mellitus, metabolic syndrome without diabetes, or neither
2 g64 weeks—
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome
2010 · Niacin for 24 weeks, followed by E/S (10/20 mg) + niacin (2 g) for 40 additional weeks · Hyperlipidaemic patients with diabetes mellitus, metabolic syndrome without diabetes, or neither
2 g24 weeks—
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome
2010 · Niacin for 24 weeks, followed by E/S (10/20 mg) + niacin (2 g) for 40 additional weeks · Hyperlipidaemic patients with diabetes mellitus, metabolic syndrome without diabetes, or neither
2 g40 weeks—
Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy
2017 · statin + ER niacin · Adults with established atherosclerotic cardiovascular disease and atherogenic dyslipidemia
1.5 g1 year—
Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy
1994 · fluvastatin+niacin combination · men and women with hypercholesterolemia; age range not reported
3 g9 weeks—
Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy
1994 · placebo+niacin combination · men and women with hypercholesterolemia; age range not reported
3 g9 weeks—
Fluvastatin with and without niacin for hypercholesterolemia
1994 · Fluvastatin group with niacin added · Patients with hypercholesterolemia and plasma LDL cholesterol levels at least 160 mg/dl after an American Heart Association phase 1 diet; age and sex not reported
3 g9 weeks—
Fluvastatin with and without niacin for hypercholesterolemia
1994 · Placebo group with niacin added · Patients with hypercholesterolemia and plasma LDL cholesterol levels at least 160 mg/dl after an American Heart Association phase 1 diet; age and sex not reported
3 g9 weeks—
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial
1994 · niacin · Patients with primary hypercholesterolemia; age and sex not reported
1.5 g26 weeks—
Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin
1996 · lovastatin 20 mg/day and niacin 500 mg 3 times/day · Patients with fasting LDL cholesterol concentrations of at least 150 mg/dl after dietary stabilization and washout of cholesterol-lowering drugs
1.5 g——
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
1998 · Plain niacin, 3.0 g/day phase · Adult men and women with primary hypercholesterolemia
3 g16 weeks—
Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)
2022 · Experimental group (SINR) · Men and women aged 45–74 with type 2 diabetes and symptomatic distal sensorimotor diabetic polyneuropathy
50 mg85 days108
Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
2024 · 10-element combination tablet · Overweight or obese adults with type 2 diabetes and mild-to-moderate painful diabetic neuropathy; mean age 63 years
18 mg26 weeks36
Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males
2017 · PWS · Apparently healthy, resistance-trained males; mean age about 21 years
60 mg8 weeks27
Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males
2017 · PWS + S · Apparently healthy, resistance-trained males; mean age about 22 years
60 mg8 weeks26
Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance
2017 · PWS · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years
60 mg1 day25
Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance
2017 · PWS + S · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years
60 mg1 day25
Short-Term Effects of a Ready-to-Drink Pre-Workout Beverage on Exercise Performance and Recovery
2017 · RTD · Recreationally active men and women aged 18–40 years with at least six months of resistance-training experience
65 mg7 days25
Improved cycling time-trial performance after ingestion of a caffeine energy drink
2009 · Red Bull Energy Drink · Trained male and female cyclists; mean age 27.3 years
40 mg1 day12
Effects of vitamin-B complex supplementation on periodontal wound healing
2005 · Vit-B · Adults with generalized moderate to severe chronic periodontitis undergoing access flap surgery; ages not reported; 13 males and 17 females enrolled across the study
50 mg30 days—
Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease
2015 · statin-NER combination · Patients with ischemic nephropathy and a history of at least 5 years of diabetes mellitus or 10 years of hypertension; age and sex not reported
500 mg16 weeks51
Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan
2006 · niacin extended-release/lovastatin tablets · Taiwanese patients with dyslipidemia
500 mg16 weeks36
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients
2012 · nicotinic acid group · Hemodialysis patients with serum phosphorus above 6 mg/dL
500 mg4 weeks20
The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients
2009 · niacinamide · Peritoneal dialysis patients with baseline plasma phosphorus >4.9 mg/dL
500 mg8 weeks8
Effect of niacin on the choroidal circulation of patients with age related macular degeneration
2004 · 500 mg niacin group · 12 AMD patients with bilateral drusen and visual acuity of 20/40 or better in the study eye; six received 500 mg niacin
500 mg1 day6
Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans
2009 · 500 mg daily nicotinamide · healthy volunteers
500 mg7 days—
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients
2013 · Group 4: D/E with active niacin and fenofibrate placebo · Adults aged 21–65 with HIV/HAART-associated dyslipidemia
500 mg24 weeks—
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients
2013 · Group 5: D/E with active fenofibrate and active niacin · Adults aged 21–65 with HIV/HAART-associated dyslipidemia
500 mg24 weeks—
Correlation of changes in HIF-1α and p53 expressions with vitamin B3 deficiency in skin cancer patients
2019 · experimental group · Non-melanoma skin cancer patients with positive HIF-1α and p53 expressions
500 mg7 days—
A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO(®)) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study)
2020 · LEVELIP DUO® · Adults aged 30–75 with moderately hypercholesterolemic, sub-optimal blood cholesterol levels, without other cardiovascular risk factors and not taking lipid-lowering drugs
27 mg8 weeks43
Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study
2019 · Nutraceutical combination · Adults aged 18–70 with low cardiovascular risk, in primary cardiovascular prevention, and LDL-C of 130–200 mg/dL
16 mg12 weeks16
Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease
2011 · Group B · Patients with ischaemic heart disease; age and sex not specified
1 g24 weeks108
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
2002 · 1000 mg/d ER niacin group · Adults with type 2 diabetes and dyslipidemia
1 g16 weeks45
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients
1994 · Combination therapy (pravastatin and nicotinic acid) · Adults with combined hyperlipidaemia, with or without non-insulin-dependent diabetes; total cholesterol ≥6.5 mmol/L and triglycerides ≥2.5 mmol/L
1 g12 weeks33
Effects of extended-release niacin on lipoprotein subclass distribution
2003 · Niacin ER 1,000 mg/day · Patients with primary hypercholesterolemia; age and sex not reported
1 g12 weeks21
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects
2001 · niacin · Patients with type IIb dyslipidemia, triglycerides 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl
1 g16 weeks11
Effect of niacin on the choroidal circulation of patients with age related macular degeneration
2004 · 250 mg niacin group · 12 AMD patients with bilateral drusen and visual acuity of 20/40 or better in the study eye; six received 250 mg niacin
250 mg1 day6
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease
2000 · niacin · Patients with peripheral arterial disease; age and sex not stated
1 g1 year—
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin
2003 · niacin ER/lovastatin 1,000/20 mg · Patients with type IIA or IIB hyperlipidemia; age and sex not specified
1 g28 weeks—
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
2004 · niacin group · Adults with known coronary heart disease and HDL-C below 45 mg/dL; mean age 67 years
1 g1 year—
Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin
1992 · 1,000 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles
1 g8 weeks—
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome
2007 · extended-release niacin · Adults with metabolic syndrome meeting Adult Treatment Panel III criteria
1 g52 weeks—
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)
2008 · NER/S 1,000/20 mg/day · High-risk patients with predominantly mixed dyslipidemia who were already at LDL cholesterol goals; ages and sex not specified
1 g24 weeks—
Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance
2009 · ER niacin treatment group · Adults with impaired glucose tolerance and HDL-C below 1.0 mmol/L, mean age 45.2 years; no additional comorbidities
1 g26 weeks—
Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome
2010 · ERN · Dyslipidemic adults with metabolic syndrome
1 g24 weeks—
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia
2013 · ERN/LRPT 1g/20mg+SIMVA (10 or 20mg) · Patients with mixed hyperlipidemia and LDL-C 130–190 mg/dL, triglycerides 150–500 mg/dL, and above their NCEP ATP III risk-based LDL-C goal
1 g12 weeks—
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia
2013 · ERN/LRPT 1g/20mg+SIMVA (10 or 20mg) · Patients with mixed hyperlipidemia and LDL-C 130–190 mg/dL, triglycerides 150–500 mg/dL, and above their NCEP ATP III risk-based LDL-C goal
1 g12 weeks—
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
2012 · ERN/LRPT · Patients with dyslipidemia; age and sex not specified
1 g12 weeks—
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
2012 · ERN/LRPT 1 g/20 mg + SIM 10 mg · Patients with dyslipidemia; age and sex not specified
1 g12 weeks—
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
2012 · ERN/LRPT 1 g/20 mg + SIM 20 mg · Patients with dyslipidemia; age and sex not specified
1 g12 weeks—
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
2012 · ERN/LRPT 1 g/20 mg + SIM 40 mg · Patients with dyslipidemia; age and sex not specified
1 g12 weeks—
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians
2013 · Extended-release niacin · Adults with isolated low HDL-C and predicted 10-year CHD risk of at least 20%, without overt CHD; men and women
750 mg12 weeks—
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia
2014 · Add-on-statin extended-release nicotinic acid/laropiprant · Patients with mixed dyslipidemia whose lipid targets were not achieved on a standard statin dose
1 g12 weeks—
A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD(+) Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial
2022 · RiaGev · Healthy active men and women aged 36–65 years
480 mg8 days18
Nicotinic acid supplementation: effects on niacin status, cytogenetic damage, and poly(ADP-ribosylation) in lymphocytes of smokers
1998 · 50 mg/day nicotinic acid group · Healthy smokers; age and sex not specified
50 mg14 weeks—
Nicotinic acid supplementation: effects on niacin status, cytogenetic damage, and poly(ADP-ribosylation) in lymphocytes of smokers
1998 · 100 mg/day nicotinic acid group · Healthy smokers; age and sex not specified
100 mg14 weeks—
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients
2013 · E/S+N · Adults aged 18–79 with hyperlipidemia, LDL-C 130–190 mg/dL and triglycerides ≤500 mg/dL
2 g24 weeks294
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration
2010 · extended-release niacin · Patients with coronary heart disease or a CHD equivalent, low LDL cholesterol and low HDL cholesterol, receiving stable statin treatment
2 g426 days154
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients
2013 · N · Adults aged 18–79 with hyperlipidemia, LDL-C 130–190 mg/dL and triglycerides ≤500 mg/dL
2 g24 weeks124
MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study
2013 · niacin · Adults over age 65 with previous cardiovascular events or documented atherosclerosis
1.5 g548 days72
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial
2000 · niacin · Adults with diabetes and diagnosed peripheral arterial disease
3 g60 weeks64
Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I
2004 · Extended-release niacin · Hypercholesterolemic subjects classified by LDL pattern A or B
1.5 g14 weeks60
Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I
2004 · Immediate-release niacin · Hypercholesterolemic subjects classified by LDL pattern A or B
3 g14 weeks59
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
2002 · 1500 mg/d ER niacin group · Adults with type 2 diabetes and dyslipidemia
1.5 g16 weeks52
Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)
1997 · Nicotinamide group · Patients aged 5–35 years with recent-onset insulin-dependent diabetes mellitus
25 mg/kg1 year42
Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia
2013 · WMER · Adults with mild-to-moderate dyslipidemia
1.5 g6 weeks40
Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia
2013 · IHN · Adults with mild-to-moderate dyslipidemia
1.5 g6 weeks40
Effect of Egg-White Protein Alone or Combined With Niacin on Nutritional Status, and Phosphorus Control in Maintenance Hemodialysis Patients: A Randomized Controlled Trial
2024 · 600 g niacin daily · Patients on maintenance hemodialysis
600 g8 weeks24
Extended-release niacin acutely suppresses postprandial triglyceridemia
2012 · extended-release niacin · Healthy, niacin-naive adults lacking all elements of metabolic syndrome; age and sex range not stated
2 g1 day22
Effects of extended-release niacin on lipoprotein subclass distribution
2003 · Niacin ER 2,000 mg/day · Patients with primary hypercholesterolemia; age and sex not reported
2 g12 weeks20
Extended-release niacin raises adiponectin and leptin
2007 · extended-release niacin · men with metabolic syndrome
1.5 g6 weeks20
Nicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study
2014 · Niaspan · Nondiabetic men with dyslipidemia and metabolic syndrome
2 g8 weeks20
Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy
2020 · ER-niacin · Adults with HIV on antiretroviral therapy, CD4 ≤ 350 cells/µl despite an undetectable viral load for at least 3 months
2 g24 weeks20
Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia
2015 · ER niacin added after fenofibric acid · Dyslipidemic participants taking atorvastatin; age and sex not reported
2 g—19
Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
2012 · ERN · Adults aged 40–69 with metabolic syndrome
2 g16 weeks15
Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome
2024 · ERN · Adults aged 40–69 with metabolic syndrome
2 g16 weeks14
Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus
1990 · nicotinic acid · Patients with non-insulin-dependent diabetes mellitus and dyslipidemia
4.5 g8 weeks13
Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass
2013 · Nicotinic acid group · Obese men; mean BMI 32.7
2 g8 weeks12
A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia
1992 · nicotinic acid group · Patients with type 2b hyperlipidaemia; age and sex not reported
3 g12 weeks7
Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV
2025 · ART intensification + nicotinamide group (arm C) · Men aged 28–52 with HIV receiving suppressive ART for at least 2 years, with CD4+ T-cell counts above 500 cells/mm³
2 g48 weeks5
Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV
2025 · dolutegravir + nicotinamide + auranofin + DC therapy group (arm F) · Men aged 25–61 with HIV receiving suppressive ART for at least 2 years, with CD4+ T-cell counts above 500 cells/mm³
2 g48 weeks5
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density
1999 · niacin and colestipol therapy · People with documented coronary disease, apolipoprotein B levels ≥125 mg/dL, and a family history of coronary artery disease; age and sex not reported
4 g——
Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study
2000 · NA · Patients with clinically well-defined atherosclerosis and isolated hypoalphalipoproteinemia
2.25 g——
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
2001 · immediate release niacin · Patients with atherogenic dyslipidemia, with total cholesterol >200 mg/dl, triglycerides 200–800 mg/dl, and apolipoprotein B >110 mg/dl; age and sex not reported.
3 g12 weeks—
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin
2003 · niacin ER/lovastatin 2,000/40 mg · Patients with type IIA or IIB hyperlipidemia; age and sex not specified
2 g28 weeks—
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin
2003 · niacin ER 2,000 mg · Patients with type IIA or IIB hyperlipidemia; age and sex not specified
2 g28 weeks—
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)
2004 · simvastatin plus niacin · Patients with coronary artery disease and low HDL cholesterol, with or without diabetes
2.4 g3 years—
Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin
1992 · 1,250 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles
1.25 g8 weeks—
Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin
1992 · 1,500 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles
1.5 g8 weeks—
Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin
1992 · 2,000 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles
2 g8 weeks—
Preferential increase in high-molecular weight adiponectin after niacin
2008 · niacin · Men with metabolic syndrome
1.5 g6 weeks—
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
2008 · 8-week niacin titration scheme · Patients with mixed dyslipidemia; age and sex not reported
2 g52 weeks—
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
2008 · 12-week niacin titration scheme · Patients with mixed dyslipidemia; age and sex not reported
2 g52 weeks—
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)
2008 · NER/S 2,000/20 mg/day · High-risk patients with predominantly mixed dyslipidemia who were already at LDL cholesterol goals; ages and sex not specified
2 g24 weeks—
Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans
2009 · 1500 mg daily nicotinamide · healthy volunteers
1.5 g7 days—
Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia
2009 · nicotinic acid plus placebo · Patients with combined hyperlipidemia; age and sex not reported
1.5 g12 weeks—
Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia
2009 · nicotinic acid plus gemfibrozil · Patients with combined hyperlipidemia; age and sex not reported
1.5 g12 weeks—
A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability
1991 · nicotinic acid · Non-diabetic patients with type II B or IV hypertriglyceridaemia; ages and sex not stated
3 g6 weeks—
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study
2009 · nicotinic acid group · Patients with low HDL-C and either type 2 diabetes with coronary heart disease or carotid/peripheral atherosclerosis; age and sex not reported
2 g1 year—
Extended-release niacin or ezetimibe and carotid intima-media thickness
2009 · extended-release niacin group · Patients with coronary heart disease or a coronary heart disease risk equivalent, receiving long-term statin therapy, with LDL cholesterol under 100 mg/dL and low HDL cholesterol
2 g426 days—
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
2010 · ER niacin · Patients with type 2 diabetes and low HDL meeting metabolic syndrome criteria
1.5 g90 days—
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy
2010 · ERN (niacin) group · Adults aged 18 years or older with HIV infection, low HDL-c, and stable antiretroviral therapy
1.5 g12 weeks—
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease
2010 · Niaspan (extended-release nicotinic acid) · Obese subjects with nonalcoholic fatty liver disease; age and sex not specified
2 g16 weeks—
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg
2010 · niacin extended release group · Patients with triglyceride levels of 150–499 mg/dL, HDL-C below 45 mg/dL and LDL-C below 130 mg/dL; age and sex not stated
1.5 g16 weeks—
Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome
2010 · ERN/LRPT · Dyslipidemic adults with metabolic syndrome
1 g24 weeks—
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study
2013 · FATS immediate-release niacin plus colestipol · Men with established coronary atherosclerosis, elevated apolipoprotein B and family history of coronary heart disease; baseline fasting glucose <100 mg/dl
4 g3 years—
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study
2013 · HATS slow-release niacin plus simvastatin · Adults with coronary artery disease, angiographic coronary atherosclerosis and low HDL cholesterol; baseline fasting glucose <100 mg/dl
2 g3 years—
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study
2013 · HATS slow-release niacin plus simvastatin and antioxidants · Adults with coronary artery disease, angiographic coronary atherosclerosis and low HDL cholesterol; baseline fasting glucose <100 mg/dl
2 g3 years—
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study
2013 · AFREGS immediate-release niacin · Military retirees with angiographically documented coronary atherosclerosis and HDL cholesterol <40 mg/dl; baseline fasting glucose <100 mg/dl
3 g3 years—
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study
2013 · CPC atorvastatin plus extended-release niacin · People with coronary or carotid artery disease, apolipoprotein B >120 mg/dl and less than one year of lipid therapy; baseline fasting glucose <100 mg/dl
2 g3 years—
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study
2013 · CPC atorvastatin plus extended-release niacin and colesevelam · People with coronary or carotid artery disease, apolipoprotein B >120 mg/dl and less than one year of lipid therapy; baseline fasting glucose <100 mg/dl
2 g3 years—
Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia
2015 · simvastatin 20 mg/extended-release niacin combination · Patients with carotid atherosclerosis; age and sex not reported
2 g——
A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography
2015 · niacin · Patients with coronary disease receiving statin therapy; age and sex not reported
6 g12 weeks—
Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol
2015 · ERN · Overweight patients with elevated triglyceride/HDL-C ratios; age and sex not specified
2 g16 weeks—
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH
2016 · ERN (extended-release niacin) · Adults aged 45 years or older with established atherosclerotic cardiovascular disease and atherogenic dyslipidemia, receiving simvastatin and ezetimibe
1.5 g3 years—
Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk
2016 · niacin monotherapy · Adults aged 18–79 years with LDL-C levels of 130–190 mg/dL and triglyceride levels below 500 mg/dL
2 g24 weeks—
Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk
2016 · triple combination therapy of E/S/N · Adults aged 18–79 years with LDL-C levels of 130–190 mg/dL and triglyceride levels below 500 mg/dL
2 g24 weeks—
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
2018 · niacin–laropiprant · Men and women aged 50–80 with a history of myocardial infarction, cerebrovascular disease, peripheral arterial disease, or diabetes with other evidence of symptomatic coronary disease
2 g4 years—
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients
1994 · Nicotinic acid alone · Adults with combined hyperlipidaemia, with or without non-insulin-dependent diabetes; total cholesterol ≥6.5 mmol/L and triglycerides ≥2.5 mmol/L
1.5 g12 weeks—
Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial
1995 · nicotinic acid · renal transplant patients with persistent hyperlipidemia despite 6 weeks of dietary treatment
3 g16 weeks—
Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia
1994 · increasing doses of crystalline niacin · Men with isolated low HDL-C and normal fasting cholesterol and triglyceride concentrations
3 g12 weeks—
Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety
1994 · Fluvastatin-niacin treated patients · Patients with hypercholesterolemia refractory to diet and LDL-C levels at least 160 mg/dL; age and sex not stated
3 g9 weeks—
Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety
1994 · Niacin-placebo control arm · Patients with hypercholesterolemia refractory to diet and LDL-C levels at least 160 mg/dL; age and sex not stated
3 g9 weeks—
Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia
1996 · 1500 mg/d CNA (ENDURACIN) phase · Men and women aged 20 to 70 years with hypercholesterolemia
1.5 g60 days—
Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia
1996 · 2000 mg/d CNA phase · Men and women aged 20 to 70 years with hypercholesterolemia
2 g60 days—
Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas
1998 · group 1: insulin plus nicotinamide · Adults with type 2 diabetes, normal body weight (BMI <25 kg/m2), no signs of autoimmunity, and secondary failure of sulphonylureas; age and sex not stated
1.5 g26 weeks—
Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas
1998 · group 3: current sulphonylureas plus nicotinamide · Adults with type 2 diabetes, normal body weight (BMI <25 kg/m2), no signs of autoimmunity, and secondary failure of sulphonylureas; age and sex not stated
1.5 g26 weeks—
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
1998 · Niaspan · Adult men and women with primary hypercholesterolemia
1.5 g16 weeks—
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
1998 · Plain niacin, 1.5 g/day phase · Adult men and women with primary hypercholesterolemia
1.5 g8 weeks—
SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs
1999 · Combination of pentifylline and nicotinic acid · Elderly volunteers aged 52–70 years, without a stated condition
200 mg60 days—
Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
2012 · Combination · Adults aged 40–69 with metabolic syndrome
2 g16 weeks13
Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome
2024 · Combination · Adults aged 40–69 with metabolic syndrome
2 g16 weeks13
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group IV (CoRN for 45 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
50 mg45 days—
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group V (CoRN for 90 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
50 mg90 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group IV (CoRN for 45 days) · Breast cancer patients treated with tamoxifen
50 mg45 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group V (CoRN for 90 days) · Breast cancer patients treated with tamoxifen
50 mg90 days—
Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy
2008 · CoRN supplement plus tamoxifen · Breast cancer patients undergoing tamoxifen therapy
50 mg——
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group IV (CoRN for 45 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
50 mg45 days—
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group V (CoRN for 90 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
50 mg90 days—
Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults
2013 · Q-1000 · Healthy adults aged 40–83 years; women and men
10 mg90 days—
Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults
2013 · Q-500 · Healthy adults aged 40–83 years; women and men
5 mg90 days—
A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial
2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases
20 mg10 weeks24
Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial
2010 · antioxidant micronutrient combination · Patients with a history of sporadic colorectal adenoma; age and sex not specified
80 mg120 days—
Effects of supplementation with low-dose group B vitamins on clinical and biochemical parameters in critically ill patients with COVID-19: a randomized clinical trial
2024 · intervention group · Critically ill patients with COVID-19
40 mg2 weeks40